Pharmaceutical Giants Unite: Glaxo Wellcome and SmithKline Beecham Merge in $163 Billion Deal

Strategic Insights -

The proposed merger between Glaxo Wellcome and SmithKline Beecham has created a pharmaceutical industry giant, valued at $163 billion, with combined sales of over $20 billion and sufficient research funds to develop new generations of drugs. This new alliance, led by Sir Richard Sykes, will position European pharmaceutical companies at the forefront of the global industry. With a massive annual cash pile of over $3 billion and a significant share of the prescription drug market, the merged group will dwarf its closest rival, Novartis.

Key Takeaways:

  • The merger creates the world's largest pharmaceutical company, valued at $163 billion and with combined sales of over $20 billion.
  • The new company will have a dominant position in the global prescription drug market, with a share of 9% and an annual cash pile of over $3 billion.
  • The merged group will have significant resources to invest in research and development, with a focus on producing new classes of drugs that treat the causes of disease, not just symptoms.
  • The companies claim that $2.5 billion can be saved through merging of duplicated operations, but this will result in the loss of at least 10,000 jobs.
  • The merger is a challenge to regulators in Britain and Brussels, with the British Monopolies and Mergers Commission and European Competition Commissioner Karel Van Miert expected to scrutinize the deal.
  • The merged company will have a strong presence in key areas such as antibiotics, central nervous system (CNS) drugs, and antivirals.
  • Sir Richard Sykes, executive chairman of the new company, will work alongside Jan Leschly, chief executive and chairman of the executive management committee, to drive the company forward.

Statistics:

  • The merged company will have a combined value of $163 billion.
  • Combined sales: over $20 billion.
  • Annual cash pile: over $3 billion.
  • Share of the prescription drug market: 9%.
  • Estimated cost savings: $2.5 billion through merging of duplicated operations.
  • Expected job losses: at least 10,000.
  • Market share of leading rival, Novartis: 5%.

Sources:

  • The Financial Times